Alnylam Pharmaceuticals
ALNY
#577
Rank
HK$273.35 B
Marketcap
HK$2,129
Share price
-0.48%
Change (1 day)
51.46%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Alnylam Pharmaceuticals (ALNY) - Total debt

Total debt on the balance sheet as of June 2024 : HK$10.16 B

According to Alnylam Pharmaceuticals 's latest financial reports the company's total debt is HK$10.16 B. A companyโ€™s total debt is the sum of all current and non-current debts.

Alnylam Pharmaceuticals - Total debt on balance sheet (from 2003 to 2024)

Total debt by year

Year Total debt Change
2023-12-31HK$10.19 B-1.17%
2022-12-31HK$10.31 B32.61%
2021-12-31HK$7.77 B92.49%
2020-12-31HK$4.04 B70.77%
2019-12-31HK$2.36 B907.34%
2018-12-31HK$0.23 B0.23%
2017-12-31HK$0.23 B-79.85%
2016-12-31HK$1.16 B
2007-12-31HK$52.74 M-25.77%
2006-12-31HK$71.05 M23.93%
2005-12-31HK$57.33 M13.74%
2004-12-31HK$50.4 M249.27%
2003-12-31HK$14.43 M

Total debt for similar companies or competitors

Company Total debt differencediff. Country
HK$0.92 B-90.94%๐Ÿ‡บ๐Ÿ‡ธ USA
HK$21.07 B 107.38%๐Ÿ‡บ๐Ÿ‡ธ USA
HK$10.67 B 5.08%๐Ÿ‡บ๐Ÿ‡ธ USA
HK$2.10 B-79.33%๐Ÿ‡บ๐Ÿ‡ธ USA
HK$5.26 M-99.95%๐Ÿ‡บ๐Ÿ‡ธ USA
HK$225.95 B 2,123.44%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
HK$198.46 B 1,852.96%๐Ÿ‡ซ๐Ÿ‡ท France
HK$147.49 B 1,351.41%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel